BackTable Vascular & Interventional

Latest Episodes:

Ep. 525 Principles to Practice: An HCC Tumor Board Mar 14, 2025

Show notes

Do you ever wish you could be a fly on the wall at a tumor board meeting? In this episode of BackTable, we’re excited to give you an insider’s view of the real case discussions that take place during hepatocellular carcinoma (HCC) tumor boards. Host Dr. Zach Berman sits down with a multidisciplinary team, including Drs. Adam Burgoyne (medical oncologist), Heather Patton (hepatologist), Siddharth Padia (interventional radiologist), and Gabriel Schnickel (transplant and hepatobiliary surgeon).

Physicians, nurses, nurse practitioners, and physician assistants can follow this link to earn CME / CE credits for completing an accredited learning activity related to this discussion:

https://www.cmeuniversity.com/course/take/125743

---

This podcast is supported by an educational grant from AstraZeneca Pharmaceuticals and Boston Scientific.

---

SYNPOSIS

The team walks through a range of diverse HCC cases, reviewing patient histories, imaging, and treatment options. They cover eight cases in total, each featuring patients with varying treatment histories, comorbidities, liver function, and lesion characteristics. For the full educational experience, we recommend watching the video format on our YouTube channel.

---

TIMESTAMPS

00:00 - Introduction

00:47 - Case 1: Small Lesion in a Young Patient

05:01 - Case 2: Moderate Sized Lesion in an Older Patient

11:10 - Case 3: Multifocal HCC with Dominant Lesion

21:09 - Case 4: Dominant Lesion with Portal Hypertension

32:08 - Case 5: Ruptured Solitary Lesion

34:34 - Case 6: Rupture with Multifocal Lesions

44:08 - Case 7: Portal Vein Invasion

52:12 - Case 8: Metastatic HCC After Transplant

---

RESOURCES

CME Accreditation Information:

https://f7cae4ec-b69e-490d-9e0f-19b16a6f146d.usrfiles.com/ugd/f7cae4_a7c37ea3cd1b4d3fa53d5edf8dfe255b.pdf

Ep. 524 Collaborative Oncology: Surgeon’s Perspective and Role in Locoregional Therapy with Dr. Robert Martin Mar 11, 2025

Show notes

Medical, surgical, radiation, and interventional oncology all play vital roles in delivering care to patients battling liver cancer. How do we optimize outcomes when so many specialties have something to offer the same patient? The answer is collaborative oncology. Dr. Robert Martin (Director of Surgical Oncology, University of Louisville) and pioneer in liver-directed therapies, joins host Dr. Sabeen Dhand to discuss a collaborative approach to oncology and recent advances in locoregional therapy.

---

This podcast is supported by:

RADPAD® Radiation Protection

https://www.radpad.com/

---

SYNPOSIS

Dr. Martin discusses the importance of a growth mindset in advancing medical techniques and fostering collaborations between specialists. He then shares insights into minimally invasive procedures, such as microwave ablation and irreversible electroporation (IRE). The doctors also touch on the evolution of liver cancer treatments, emphasizing the significance of clinical trials on the horizon. To conclude, Dr. Martin encourages young professionals in surgery and interventional radiology to stay open-minded, be life-long learners, and find synergistic ways to integrate new technologies into patient care.

---

TIMESTAMPS

00:00 - Introduction

02:31 - Dr. Martin’s Background and Career Path

06:18 - Evolution of Liver Directed Therapies

10:12 - Collaboration Between Specialties

18:34 - Clinical Trials and Emerging Therapies

36:08 - Advice for Young Professionals

39:15 - Conclusion

---

RESOURCES

Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of HCC:

https://clinicaltrials.gov/study/NCT05953337?term=NCT05953337&rank=1

Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS (INJECTABL-1):

https://clinicaltrials.gov/study/NCT05688280

Immunophotonics, CIRSE, and Next Research Announce Innovative Phase 2/3 Clinical Trial: INJECTABL-3:

https://immunophotonics.com/news/immunophotonics-cirse-and-next-research-announce-innovative-phase-2-3-clinical-trial-injectabl-3/

Ep. 523 Getting Started in Interventional Oncology: Tips for Starting your Career Mar 07, 2025

Show notes

Are you seeking to build your reputation and patient base within interventional oncology? In this episode, host Dr. Zachary Berman interviews Dr. Siddarth Padia, Dr. Tyler Sandow, Dr. Kavi Krishnasamy, and Dr. Kevin Burns about their journeys into interventional oncology (IO) and their experiences providing care in different practice settings.

Physicians, nurses, nurse practitioners, and physician assistants can follow this link to earn CME / CE credits for completing an accredited learning activity related to this discussion:

https://www.cmeuniversity.com/course/take/125742

---

This podcast is supported by an educational grant from AstraZeneca Pharmaceuticals and Boston Scientific.

---

SYNPOSIS

The doctors begin by discussing how they became interested in interventional oncology, with most of them recognizing opportunities to address unmet needs in the field. Each guest shares insights on the timelines and challenges involved in starting their IO practices, which vary significantly today. For instance, telehealth clinics are particularly viable in private practice IO, thanks to conferencing software and virtual translators. Hybrid care models, which combine in-person and remote consultations, can help overcome patient-level barriers such as time and transportation. The panel also emphasizes how increased clinic availability can significantly drive growth in procedural volume. Finally, they offer advice for starting an IO practice, including the importance of having clinic support staff, building strong relationships with referring physicians, and staying up to date with new technologies.

---

TIMESTAMPS

00:00 - Introduction

05:38 - Balancing Career Interests and Expectations

07:10 - Building an Interventional Oncology Practice

13:42 - Gaining Trust from Referring Physicians

17:33 - Importance of Open Communication

19:19 - Comparing Clinic Settings

26:01 - Essential Components of a Clinic

33:28 - Narrowing Your Interventional Practice

40:09 - Introducing New Technology

---

RESOURCES

CME Accreditation Information:

https://f7cae4ec-b69e-490d-9e0f-19b16a6f146d.usrfiles.com/ugd/f7cae4_a7c37ea3cd1b4d3fa53d5edf8dfe255b.pdf

Ep. 522 Advancements in Treatment of Metastatic Ocular Melanoma with Dr. Altan Ahmed and Dr. Sid Padia Mar 04, 2025

Show notes

Is there a way to treat liver metastasis secondary to uveal melanoma without introducing systemic, treatment-related toxicity? Dr. Altan Ahmed (interventional radiologist at Moffitt Cancer Center) and Dr. Sid Padia (interventional radiologist at UCLA) join guest-host Dr. Kavi Krishnasamy to discuss HEPZATO, a novel device-based treatment for liver metastases from uveal melanoma.

---

This podcast is supported by:

RADPAD® Radiation Protection

https://www.radpad.com/

---

SYNPOSIS

Dr. Ahmed and Dr. Padia begin by exploring the design and setup of the HEPZATO clinical trials, while also speaking on patient selection criteria. The doctors then talk through the technical aspects of the intervention. After covering workflow and considerations related to procedure timing and coordination, the doctors go on to discuss drug dosing and optimizing treatment cycles. The episode concludes with current gaps in literature, current and future research aims, and potential future applications of the HEPZATO modality in treating other malignancies such as colorectal cancer.

---

TIMESTAMPS

00:00 - Introduction

05:40 - Patient Selection Criteria

09:49 - Workflow

19:17 - Procedure Timing and Coordination

29:39 - Challenges and Considerations in Drug Dosing

32:39 - Optimizing Treatment Cycles and Patient Response

37:56 - Managing Post-Treatment and Adverse Effects

43:43 - Future Research and Gaps in Current Interventions

50:45 - Exploring New Applications for PHP Therapy

55:02 - Conclusion

---

RESOURCES

Hepzato:

https://hepzatokit.com/

FOCUS Trial - Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study:

https://pubmed.ncbi.nlm.nih.gov/38704501/

FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A):

https://ascopubs.org/doi/pdf/10.1200/JCO.2022.40.16_suppl.9510

Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial:

https://pubmed.ncbi.nlm.nih.gov/36624292/

Troponin Elevation in Patients Undergoing Percutaneous Hepatic Perfusion for Metastatic Uveal Melanoma:

https://pmc.ncbi.nlm.nih.gov/articles/PMC11010739/

Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study:

https://pmc.ncbi.nlm.nih.gov/articles/PMC7801354/

Southampton group - Quality of life after melphalan percutaneous hepatic perfusion for patients with metastatic uveal melanoma:

https://pmc.ncbi.nlm.nih.gov/articles/PMC10906212/

Leiden group - Quality of Life Analysis of Patients Treated with Percutaneous Hepatic Perfusion for Uveal Melanoma Liver Metastases:

https://pubmed.ncbi.nlm.nih.gov/38587534/

Ep. 521 Surgery for HCC: What’s its Role Today? Feb 28, 2025

Show notes

Is surgery truly the "cure" for hepatocellular carcinoma (HCC), and when is it a viable option? In this episode, Dr. Sabeen Dhand leads a roundtable discussion with interventional radiologist Dr. Siddharth Padia and transplant/hepatobiliary surgeons Dr. John Seal and Dr. Gabriel Schnickel, delving into the complexities of surgical treatments for HCC and the evolving landscape of liver resection and transplantation.

Physicians, nurses, nurse practitioners, and physician assistants can follow this link to earn CME / CE credits for completing an accredited learning activity related to this discussion:

https://www.cmeuniversity.com/course/take/125741

---

This podcast is supported by an educational grant from AstraZeneca Pharmaceuticals and Boston Scientific.

---

SYNPOSIS

The doctors begin by discussing how they manage patient expectations regarding both palliative and curative treatments, highlighting the risk of recurrent HCC as a new lesion. They then outline key factors that influence their recommendations for liver transplant versus resection, such as the extent of underlying liver disease, the function of the future liver remnant, body habitus, overall health, and organ availability. The surgeons also review various surgical approaches to liver resection and recent advancements in liver transplantation, including living donor transplants and the ability to refer patients for downstaging procedures.

Dr. Padia explains the original role of Y90 as a bridging treatment to downstage tumors and promote hypertrophy in the non-diseased liver segments, preparing the organ for surgical resection. However, Y90 treatment can also lead to the formation of adhesions, which may complicate future surgeries. Finally, the doctors discuss strategies to improve care coordination between community physicians and transplant centers to optimize patient outcomes.

---

TIMESTAMPS

00:00 - Curative vs. Palliative Treatment

04:03 - Choosing Between Transplantation and Resection

05:47 - Liver Resection Types

07:27 - Bridging Role of Y90

12:14 - Evolving Landscape of Liver Transplantation

20:59 - Patient Counseling in Minimally Invasive Procedures

28:40 - Considerations for Surgery After Y90

33:32 - Coordination Between Specialists

40:08 - Immunotherapy as a Bridge to Transplant

---

RESOURCES

CME Accreditation Information:

https://f7cae4ec-b69e-490d-9e0f-19b16a6f146d.usrfiles.com/ugd/f7cae4_a7c37ea3cd1b4d3fa53d5edf8dfe255b.pdf

Ep. 520 Frontiers in Musculoskeletal Embolization with Dr. Yuji Okuno Feb 25, 2025

Show notes

Musculoskeletal embolization is generating significant excitement in the field of chronic pain management. In this episode, Dr. Jacob Fleming hosts a discussion with Dr. Yuji Okuno from Japan, a pioneer in both basic science and clinical practice within the field of musculoskeletal embolization.

---

This podcast is supported by:

Medtronic MVP

https://www.medtronic.com/mvp

---

SYNPOSIS

The conversation delves into Dr. Okuno's groundbreaking work using embolization to treat chronic pain from conditions such as frozen shoulder, knee osteoarthritis, plantar fasciitis, and various sports injuries. Dr. Okuno discusses the development of new temporary embolic agents and compares different approaches to embolization treatments, including the innovative use of antibiotics as embolic material. The doctors also cover the intriguing concept of differential recanalization, where abnormal inflammatory vessels are less likely to recanalize than normal vessels after embolic treatment. Identifying hypervascularity through MRI, ultrasound, or angiogram is a crucial step before attempting embolization.

Overall, Dr. Okuno offers valuable insights into his clinical practice and the potential for groundbreaking advancements in musculoskeletal care worldwide.

---

TIMESTAMPS

00:00 - Introduction

01:54 - Origins of Embolization for Pain

04:15 - Basic Science Research Discoveries and Clinical Trials

09:02 - Temporary Embolic Materials

15:28 - Techniques for Embolization

17:33 - Plantar Fasciitis Treatment

24:04 - Future of Embolization in Sports Injuries

28:11 - Diagnostic Imaging in Embolization

36:10 - Global Expansion and Collaborations

Ep. 519 Transplantation for HCC: Who, When, and How? Feb 21, 2025

Show notes

The process of liver transplantation involves many complexities, and each patient's path to transplant is unique. To offer insider perspectives on this process, Dr. Zachary Berman sits down with transplant and hepatobiliary surgeon Dr. John Seal, as well as transplant hepatologists Dr. Heather Patton and Dr. Steve Young.

Physicians, nurses, nurse practitioners, and physician assistants can follow this link to earn CME / CE credits for completing an accredited learning activity related to this discussion:

https://www.cmeuniversity.com/course/take/125740

---

This podcast is supported by an educational grant from AstraZeneca Pharmaceuticals and Boston Scientific.

---

SYNPOSIS

The panel begins by discussing the multidisciplinary pre-transplant evaluation process, which assesses factors such as liver function, comorbidities, surgical risk, and the availability of psychosocial support. Once a patient is listed for transplant, they enter a system that prioritizes those with the highest Model for End-Stage Liver Disease (MELD) score. During the waiting period, several comorbidities should be carefully monitored. Dr. Seal explores the impact of portal vein hypertension and portal vein thrombosis, explaining how these conditions may necessitate intraoperative thrombectomy or bypass. Dr. Patton and Dr. Young focus on considerations for using anticoagulation in patients with a high baseline bleeding risk and selecting the appropriate anticoagulant for patients listed for transplant.

For patients with hepatocellular carcinoma (HCC), eligibility for MELD exception points may depend on factors such as time spent on the waiting list, adherence to the Milan criteria, and the presence of extrahepatic complications of liver disease. The panel also discusses bridging therapies to transplant, including Y90 and TACE. In the peri-transplant phase, they highlight innovations such as living donor transplants, liver perfusion pumps, and the use of hepatitis C- and HIV-positive organs. Finally, the discussion turns to post-transplant considerations, including surgical complications, organ rejection, immunosuppression, predictors of HCC recurrence, and long-term surveillance.

---

TIMESTAMPS

00:00 - Introduction

01:16 - Current Landscape of Liver Transplantation

03:22 - Transplant Evaluation Process

09:48 - Timeline from Listing to Transplantion

11:16 - Treating Portal Vein Thrombosis and Hypertension

18:44 - MELD Exception Points

22:05 - Bridging Therapies

25:34 - Peri-Transplant Considerations

30:53 - Post-Transplant Period

37:39 - Repeat Transplantation

---

RESOURCES

Model for end-stage liver disease (MELD) and allocation of donor livers (Wiesner et al, 2003):

https://www.gastrojournal.org/article/S0016-5085%2803%2950022-1/fulltext

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis- Milan Criteria (Mazzaferro et al, 1996):

https://pubmed.ncbi.nlm.nih.gov/8594428/

Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database (Mehta et al, 2019):

https://pmc.ncbi.nlm.nih.gov/articles/PMC6445634/

CME Accreditation Information:

https://f7cae4ec-b69e-490d-9e0f-19b16a6f146d.usrfiles.com/ugd/f7cae4_a7c37ea3cd1b4d3fa53d5edf8dfe255b.pdf

Ep. 518 Long-Term Outcomes of Prostatic Artery Embolization (PAE) with Dr. Shivank Bhatia Feb 18, 2025

Show notes

Do we finally have definitive data on the efficacy of prostate artery embolization (PAE)? Dr. Shivank Bhatia (interventional radiologist at University of Miami) joins host Dr. Michael Barraza to discuss the findings from his prospective 1,075 patient study on the long-term outcomes of PAE, the largest longitudinal, single-center, single-operator, prospective study in the United States.

---

This podcast is supported by:

RADPAD® Radiation Protection

https://www.radpad.com/

Medtronic MVP

https://www.medtronic.com/mvp

---

SYNPOSIS

Dr. Bhatia begins by sharing his early years of training, and the steps he took to become an expert in all things PAE. He also covers how he helped build the PAE program at University of Miami, sharing several pearls for young IRs and trainees that are interested in bringing new service lines to their institutions. Dr. Bhatia then talks through the details of the study that he spearheaded, and encourages everyone to tune in - physicians and patients alike.

---

TIMESTAMPS

00:00 - Introduction

05:12 - Building a PAE Program

18:55 - PAE Procedure Technicalities

22:30 - Post-Procedure Meds and Care

25:13 - Study Details and Patient Demographics

27:36 - Procedure Time and Technical Success

28:32 - Safety and Efficacy of PAE

38:06 - PSA Levels and Prostate Cancer

40:42 - Urinary Retention and Treatment Prioritization

45:17 - Re-Intervention Rates and Medication Independence

---

RESOURCES

Pisco et al (2011) - Prostatic arterial embolization to treat benign prostatic hyperplasia:

https://pubmed.ncbi.nlm.nih.gov/21195898/

Bhatia et al (2024) - Prostatic Artery Embolization: Mid- to Long-Term Outcomes in 1,075 Patients:

https://pubmed.ncbi.nlm.nih.gov/39532156/

Ep. 517 Complex HCC Patients and the "Grey Zone": What to Do When You Don’t Know What to Do Feb 14, 2025

Show notes

Treatment of hepatocellular carcinoma (HCC), like that of many other cancers, spans a spectrum from curative to palliative intent. To explore the "grey zone" of treatment goals for intermediate-stage HCC patients, Dr. Sabeen Dhand interviews a panel of experts in the field: medical oncologists Dr. Adam Burgoyne and Dr. Lingling Du, along with interventional radiologists Dr. Kirema Garcia-Reyes and Dr. Zachary Berman.

Physicians, nurses, nurse practitioners, and physician assistants can follow this link to earn CME / CE credits for completing an accredited learning activity related to this discussion:

https://www.cmeuniversity.com/course/take/125739

---

This podcast is supported by an educational grant from AstraZeneca Pharmaceuticals and Boston Scientific.

---

SYNPOSIS

The discussion begins with an explanation of the Barcelona-Clinic Liver Cancer (BCLC) staging system. While this system takes into account helpful factors such as liver function, performance status, and tumor burden, it fails to fully capture the true heterogeneity of the HCC patient population. Additional considerations include tumor biology, response to previous treatments, and the location of metastases. The specialists then share their experiences in treating patients with comorbid gastrointestinal cancers and mixed tumors, discuss the benefits of an interventional oncology clinic setting, and highlight virtual opportunities for connecting with tumor boards. They also offer advice on patient education regarding treatment options.

---

TIMESTAMPS

00:00 - Introduction to BCLC Staging

03:02 - Impact of Performance Status

06:29 - Predictors of Survival in HCC

09:51 - Palliative versus Curative Treatment Intent

13:55 - Comorbid and Mixed Gastrointestinal Cancers

16:51 - Adverse Effects of Treatment

20:37 - Interventional Oncology in the Clinic Setting

23:06 - Navigating Multiple Provider Viewpoints

28:01 - Complex Case Examples

---

RESOURCES

BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update (Reig et al, 2022):

https://www.journal-of-hepatology.eu/article/S0168-8278(21)02223-6/fulltext

CME Accreditation Information:

https://f7cae4ec-b69e-490d-9e0f-19b16a6f146d.usrfiles.com/ugd/f7cae4_a7c37ea3cd1b4d3fa53d5edf8dfe255b.pdf

Ep. 516 Dialysis Procedures: New Tools for Better Outcomes with Dr. Ari Kramer and Dr. Omar Davis Feb 11, 2025

Show notes

Given the challenges that our dialysis patients face, how can we as providers stay sharp with the latest access techniques to help ensure the best possible outcomes? Dr. Omar Davis (interventional nephrologist) and Dr. Ari Kramer (general surgeon) join host Dr. Chris Beck to discuss advanced approaches to AV access and share their experiences with the FLEX Vessel Prep device.

---

This podcast is supported by:

VentureMed FLEX Vessel Prep

https://www.venturemedgroup.com/

---

SYNPOSIS

The doctors begin by describing how they create dialysis access and what they account for during the procedure. They then focus on the role of the FLEX VP system, its benefits, and how they use it in practice, touching on the latest clinical data. Dr. Kramer and Dr. Davis also stress the importance of mental health in dialysis care and share ways that we can better support our patients through difficult diagnoses and treatments. In fact, one of their patients, Fred Hill, authored the book “Dialysis Is Not Your Life,” which offers a unique perspective for patients feeling overburdened by dialysis, and the healthcare providers who treat them. The episode concludes with case presentations and practical guidance on when to use the FLEX Vessel Prep system.

---

TIMESTAMPS

00:00 - Introduction

07:00 - AV Access and Procedures

10:58 - Case Walkthrough

14:19 - Balloon Angioplasty and IVUS

24:43 - Flex VP Device and Vessel Prep

35:03 - Algorithm and Reimbursement Challenges

39:51 - Device Usage and Techniques

46:58 - Clinical Data and Outcomes

01:01:59 - Case Studies

---

RESOURCES

Fred Hill, “Dialysis Is Not Your Life” Founder and Author:

https://www.dialysisisnotyourlife.com/meet-founder.php

“Dialysis Is Not Your Life” Book:

https://www.amazon.com/DIALYSIS-NOT-YOUR-LIFE-Redefine/dp/B09L4XGGNX

Novel Device Prior to Balloon Angioplasty for Dysfunctional Arteriovenous Access: Analysis of a Real-World Registry by Race and Sex Cohorts:

https://www.openaccessjournals.com/articles/novel-device-prior-to-balloon-angioplasty-for-dysfunctional-arteriovenousaccess-analysis-of-a-realworld-registry-by-race-and-sex-16852.html

FLEX Vessel Prep 12 Month AV Registry Data and 12 Month Belong PAD Data Shows Benefit to Micro-incisions Before Balloon or DCB Treatment:

https://www.venturemedgroup.com/wp-content/uploads/2022/12/VEITH-Data-FINAL.pdf

Angioplasty with novel, easy-to-use, bladed Flex Vessel Prep system “could replace standard of care”:

https://www.youtube.com/watch?v=iRpkrURx1mc

Surgical AVF Articles Atlas Condensed - sAVF Overview - Creation Maturation and Difficulties:

https://docs.google.com/document/d/1f26FT65s03oZjjeZhBVy8auz0h8PTNvX3CWU5Xi_H5c/edit?usp=share_link

Surgical AVF Articles Asif A, Early Arteriovenous fistula failure:

https://drive.google.com/file/d/1zZEWgxsdBM4MKCQFjw0U04ra_hB9Ey_N/view?usp=share_link

Surgical AVF Articles Asif A - Best Vascular Access in the Elderly - Time for Innovation:

https://drive.google.com/file/d/1IpH-KnZyfN5Rqm_kxLnERnEJD6vcjAO8/view?usp=sharing

Surgical AVF Articles EV Today - Managing Cephalic Arch Stenosis:

https://drive.google.com/file/d/17yVd2M706YCtX-xTK6teesgZqzVIgUoN/view?usp=share_link

VentureMed 2024 FLEX Vessel Prep System Reimbursement Guide:

https://www.venturemedgroup.com/wp-content/uploads/2024/04/MMA-CTO-15690_FlexVesselPrepSystem-BillingGuide_Lv6-003.pdf

BackTable VI Podcast Episode #139 - AV Fistula & Graft Maintenance with Dr. Ari Kramer:

https://www.backtable.com/shows/vi/podcasts/139/av-fistula-graft-maintenance

BackTable VI Podcast Episode #292 - Dialysis Interventions with Drug-Coated Balloons, Covered Stents and More with Dr. Ari Kramer:

https://www.backtable.com/shows/vi/podcasts/292/dialysis-interventions-with-drug-coated-balloons-covered-stents-more

Our TOPPODCAST Picks

Follow Us

Stay Connected

BackTable Vascular & Interventional

Related Podcasts

Links

Stay Connected